Investment Type: Venture Capital
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| 22.10.2025 | Ena Respir... | enarespiratory.com | $51.4M | Australia |
| 08.09.2025 | NRG Therap... | nrgtherapeutics.com | $86.46M | United Kin... |
| 28.08.2025 | Vaxxas | vaxxas.com | $128.76M | Australia |
Mentions in press and media 20
| Date | Title | Description |
| 07.01.2026 | AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board | London, UK, 7 January 2026 – Astronautx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, today announces the appointment of Ad... |
| 22.10.2025 | ENA Respiratory Raises US$22.4M in Series B Financing | ENA Respiratory, a Melbourne, Australia-based clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, raised US$22.4m (AUD$34m) in Series B financ... |
| 08.09.2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases. The round... |
| 08.09.2025 | NRG Therapeutics Raises £50M Series B Financing | NRG Therapeutics, a Stevenage, UK-based neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, raised £50M in Series B funding. The round was led by Health Investors’ Dementia Discovery Fund, alongside other ... |
| 28.08.2025 | Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery Technology | Vaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a... |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 09.06.2022 | Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board | Promising 'dark matter' cancer therapy has clinical trials in sight DUNEDIN, New Zealand, June 9, 2022 /PRNewswire/ -- Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in can... |
| 15.06.2021 | ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round | Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory th... |
Show more